Adamas Pharmaceuticals, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) (“Adamas” or the “Company”) with Supernus Pharmaceuticals, Inc. (“Supernus”). Upon the closing of the transaction, Supernus will acquire Adamas through a tender offer for $8.10 per share in cash payable at closing plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash for a total consideration of $9.10 per share in cash.

The Adamas merger investigation concerns whether the Board of Adamas has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.